Olanzapine Teva 15 mg Orodispersible tablet
Authorisation EU/1/07/427/31-34 · Teva Pharma B.V.
- Licence holder
- Teva Pharma B.V. (all products →)
- Active substance
- Olanzapine
- Clinical trials
- 18 clinical trials →
- Dosage form
- Orodispersible tablet
- Route of administration
- Oral use
- ATC codes
- N05AH, N05AH03
- First authorised
- 12/12/2007
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Hybrid application (Article 10(3) of Directive No 2001/83/EC)
Olanzapine: supply and approvals
79 authorised products on the HPRA list contain Olanzapine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- Zypadhera: Shortage ongoing, first published 9 Jul 2024
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 21 Nov 2026)
- Germany (BfArM)
- 8 supply notices, e.g. Olanzapin Glenmark 2,5 mg Tabletten - OP56 (21 Sep 2026 to 11 Dec 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 427. It has been authorised for 18 years (since 12 December 2007). The HPRA list does not say whether it is on sale.
Other medicines with Olanzapine in Ireland
78 other products on the HPRA list contain Olanzapine, from 10 licence holders; 13 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Olanzapine 10mg Film-coated Tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Olanzapine 15mg Film-coated Tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Olanzapine 2.5mg Film-coated Tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Olanzapine 20mg Film-coated Tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Olanzapine 5mg Film-coated Tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Olanzapine 7.5mg Film-coated Tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Olanzapine Accord 10 mg film-coated tablets | Accord Healthcare Ireland Limited | National authorisation (PA) | Marketed |
| Olanzapine Accord 15 mg film-coated tablets | Accord Healthcare Ireland Limited | National authorisation (PA) | Marketed |
| Olanzapine Accord 2.5 mg film-coated tablets | Accord Healthcare Ireland Limited | National authorisation (PA) | Marketed |
| Olanzapine Accord 5 mg film-coated tablets | Accord Healthcare Ireland Limited | National authorisation (PA) | Marketed |
| Rolyprexa 10 mg film-coated tablets | Rowex Limited, | National authorisation (PA) | Marketed |
| Rolyprexa 5 mg film-coated tablets | Rowex Limited, | National authorisation (PA) | Marketed |
Other substances in ATC group N05AH
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 8 other active substances share the group N05AH with this product:
Quetiapine (41) · Clozapine (12) · Quetiapine fumarate (7) · Quetiapine hemifumarate (3) · Olanzapine pamoate monohydrate (3) · Loxapine (2) · Asenapine maleate (2) · Olanzapine form 1 (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Teva Pharma B.V. holds 155 products on the HPRA list, with 69 different active substances; 100 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.